3:55 AM
 | 
Apr 09, 2018
 |  BioCentury  |  Finance

Epigenetic experience

Why founding investor TCG returned for Constellation’s $100M round

Constellation Pharmaceuticals Inc.’s scientific team and deep epigenetics pipeline enabled the company to garner an untranched $100 million venture round.

New investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed Advisors and Sirona Capital participated along with existing investors The Column Group, Third Rock Ventures, Venrock, SR One, the University of California Investment Office, Topspin Partners and Casdin Capital.

Constellation has raised $277 million in venture funding since its launch in 2008.

Peter Svennilson of TCG, a founding investor, told BioCentury, “Despite being a 10-year-old company, Constellation has a substantial research group still...

Read the full 468 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD